Vimarsana
Biggest News Aggregation in the World

Linong Ji News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linong Ji. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linong Ji Today - Breaking & Trending Today

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions - Vimarsana News

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

Published: June 12, 2024

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com
Related Topics:
United StatesAdimab IncyteInnovent BiologicsEli LillyLinong JiUniversity People HospitalClinical Development Of InnoventCompany LillyPrnewswire Innovent Biologics IncAmerican Diabetes AssociationMd Anderson Cancer CenterScientific SessionsChinese ParticipantsPoster TheaterPeking University PeopleLiver SteatosisChinese AdultsLei QianVice PresidentClinical Development
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China - Vimarsana News

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China

Published: February 7, 2024

ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Source: marketscreener.com
Related Topics:
United StatesHong KongInnovent BiologicsLinong JiAdimab IncyteEli LillyCompany LillyClinical Development Of InnoventMd Anderson Cancer CenterUniversity People HospitalNational Medical Products AdministrationIncyte CorporationInstitute For Health MetricsPrnewswire Innovent Biologics IncGlobal Health Data ExchangeNew Drug ApplicationDrug EvaluationPeking University PeopleLei QianVice PresidentClinical DevelopmentMainland ChinaLancet Diabetes EndocrinolHealth MetricsGlobal Health Data
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA - Vimarsana News

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

Published: January 9, 2024

ROCKVILLE, Md. and SUZHOU, China, Jan. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Source: marketscreener.com
Related Topics:
Hong KongUnited StatesAdimab IncyteInnovent BiologicsLinong JiEli LillyChina National Medical Products AdministrationGlobal Health Data ExchangeClinical Development Of InnoventUniversity People HospitalIncyte CorporationCompany LillyInstitute For Health MetricsPrnewswire Innovent Biologics IncMd Anderson Cancer CenterDrug EvaluationNational Medical Products AdministrationPeking University PeopleLei QianVice PresidentClinical DevelopmentCancer CenterMainland ChinaLancet Diabetes EndocrinolHealth Metrics
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity - Vimarsana News

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

Published: January 2, 2024

ROCKVILLE, Md. and SUZHOU, China, Jan. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Source: marketscreener.com
Related Topics:
Hong KongUnited StatesLinong JiInnovent BiologicsAdimab IncyteEli LillyInstitute For Health MetricsIncyte CorporationPrnewswire Innovent Biologics IncClinical Development At InnoventCompany LillyGlobal Health Data ExchangeUniversity People HospitalMd Anderson Cancer CenterInnovent Rd CodePeking University PeopleLei QianVice PresidentClinical DevelopmentSintilimab InjectionBevacizumab InjectionAdalimumab InjectionRituximab InjectionPemigatinib Oral InhibitorRamucirumab Injection
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications - Vimarsana News

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Published: December 18, 2023

/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesInnovent BiologicsAdimab IncyteEli LillyLinong JiCompany LillyPrnewswire Innovent Biologics IncNature CommunicationsMd Anderson Cancer CenterIncyte CorporationUniversity People HospitalClinical Development Of InnoventGlobal Health Data ExchangeInstitute For Health MetricsPeking University PeopleLei QianVice PresidentClinical DevelopmentSintilimab InjectionBevacizumab InjectionAdalimumab InjectionRituximab InjectionPemigatinib Oral InhibitorRamucirumab Injection